Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology. American journal of preventive cardiology Virani, S. S., Aspry, K., Dixon, D. L., Ferdinand, K. C., Heidenreich, P. A., Jackson, E. J., Jacobson, T. A., McAlister, J. L., Neff, D. R., Gulati, M., Ballantyne, C. M. 2023; 13: 100472

Abstract

Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the leading cause of morbidity and mortality in the United States, national quality assurance metrics no longer include LDL-C measurement as a required performance metric. This clinical perspective reviews the history of LDL-C as a quality and performance metric and the events that led to its replacement. It also presents patient, healthcare provider, and health system rationales for re-establishing LDL-C measurement as a performance measure to improve cholesterol control in high-risk groups and to stem the rising tide of CVD morbidity and mortality, cardiovascular care disparities, and related healthcare costs.

View details for DOI 10.1016/j.ajpc.2023.100472

View details for PubMedID 36970638

View details for PubMedCentralID PMC10037190